Price movement over the last 24 hours
Abbott Laboratories vs Amplitude Inc — how do they compare? Abbott Laboratories trades at $95.23 (market cap $166.94B), while Amplitude Inc trades at $9 (market cap $1.21B). The key difference: Abbott Laboratories is far larger — about 138× Amplitude Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Amplitude Inc pays none. Which is the better fit depends on your goals.
| ABT | AMPL | |
|---|---|---|
Market Cap | $166.94B | $1.21B |
Sector | Health | Technology |
52-Week High | $136.62 | $13.29 |
52-Week Low | $82.57 | $5.61 |
Enterprise Value | $193.69B | $1.04B |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Amplitude (AMPL) trades at $9.16, up 3.62% on the day, with a bullish technical signal from moving averages. Revenue growth is solid at $343M in 2025, but net losses persist at -$89M. Analyst consensus is 66.7% buy with a $9.00 target. Recent news highlights improving fundamentals but also legal investigations.
The outlook is mixed: strong revenue growth and analyst support offer upside, but profitability challenges and legal risks pose headwinds. Investors should weigh the bullish technicals and growth potential against ongoing losses and regulatory scrutiny for balanced risk-reward assessment.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →